Kymera Therapeutics
KYMR
157 hedge funds and large institutions have $2.01B invested in Kymera Therapeutics in 2024 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 59 increasing their positions, 49 reducing their positions, and 30 closing their positions.
38% more call options, than puts
Call options by funds: $961K | Put options by funds: $698K
20% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 49
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
0.2% less ownership
Funds ownership: 110.02% → 109.83% (-0.2%)
4% less funds holding
Funds holding: 164 → 157 (-7)
17% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 30
26% less capital invested
Capital invested by funds: $2.7B → $2.01B (-$691M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$17.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$16M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$15.3M |
| 4 |
UBS AM
Chicago,
Illinois
|
+$8.78M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$8.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$26.4M |
| 2 |
JP Morgan Chase
New York
|
-$14.2M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$12.4M |
| 4 |
Barclays
London,
United Kingdom
|
-$9.38M |
| 5 |
Citigroup
New York
|
-$6.97M |
KYMR Hedge Fund Activity: Q2 2024 in Review
157 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q2 2024, worth a combined $2.01B — down 26% from $2.7B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of KYMR and 25 opened new positions — a net loss of 5 holders — while 49 trimmed existing stakes and 59 added.
The largest buyer was BlackRock, adding an estimated $17.3M. The largest seller was State Street, cutting an estimated $26.4M.
- 157 institutional investors held Kymera Therapeutics (KYMR) as of Q2 2024, down from 164 in Q1 2024.
- Funds reported $2.01B of Kymera Therapeutics stock for Q2 2024, down 26% quarter-over-quarter.
- 25 funds opened new Kymera Therapeutics positions in Q2 2024 and 30 closed out, a net change of -5 holders.
- The largest Kymera Therapeutics buyer in Q2 2024 was BlackRock, an estimated $17.3M added.
- The largest Kymera Therapeutics seller in Q2 2024 was State Street, an estimated $26.4M sold.
Based on aggregated 13F filings for Q2 2024.